Evidence map›Paper›PMID 35956001›Full record

ArticleJournal of clinical medicine2022

Pentraxin 3 and

Shiri Meron-Sudai, Arava Reizis, Sophy Goren, Anya Bialik, Amit Hochberg, Dani Cohen

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shiri Meron-SudaiSchool of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
Arava ReizisSchool of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
Sophy GorenSchool of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
Anya BialikSchool of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
Amit HochbergNewborn and Neonatal Care Department, Hillel Yaffe Medical Center, Hadera 38100, Israel.
Dani CohenSchool of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.ORCID 0000-0003-2664-2303
Tel Aviv University · ILHillel Yaffe Medical Center · IL

Funding

European Union Seventh Framework Program 261472 STOPENTERICS
6 · The paper itself

Abstract

Shigella causes moderate to severe diarrhea or dysentery after invading the colon mucosa. Long Pentraxin 3 (PTX3) is recognized as the humoral component of the innate immune response to bacterial pathogens. We examined the interplay between levels of PTX3 and levels of anti-Shigella lipopolysaccharide (LPS) and anti-Shigella type 3 secretion system protein-IpaB antibodies in children during acute shigellosis and after recovery. PTX3 concentrations in serum and stool extracts were determined by sandwich ELISA using commercial anti-PTX3 antibodies. Serum IgG, IgM, and IgA anti-S. sonnei LPS or anti-S. sonnei IpaB were measured using in house ELISA. Children with acute shigellosis (n = 60) had elevated PTX3 levels in serum and stools as compared with recovered subjects (9.6 ng/mL versus 4.7 ng/mL, p < 0.009 in serum and 16.3 ng/g versus 1.1 ng/g in stool, p = 0.011). Very low levels of PTX3 were detected in stools of healthy children (0.3 ng/g). Increased serum levels of PTX3 correlated with high fever accompanied by bloody or numerous diarrheal stools characteristic of more severe shigellosis while short pentraxin; C-Reactive Protein (CRP) did not show such a correlation. PTX3 decreased in convalescence while anti-Shigella antibodies increased, switching the response from innate to adaptive toward the eradication of the invasive organism. These data can inform the development of Shigella vaccines and treatment options.

Indexed as

c-reactive protein (CRP)invasion plasmid antigen B (IpaB)Lipopolisaccharide (LPS)pentraxin 3 (PTX3)Shigella

Identifiers

PMID35956001
PMCPMC9368894
OpenAlexW4288442484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.